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ABSTRACT
DNAzymes are a novel class of gene suppressors that selectively bind to an 
RNA substrate by Watson-Crick base pairing and cleave phosphodiester bonds. To 
explore the potential for therapeutic use of catalytic DNA molecules, active DNAzymes 
targeting the bcl-xL gene were generated through a multiplex in vitro selection. The 
DNAzyme-mediated down-regulation of the bcl-xL expression was demonstrated in 
various cancer cell lines by Western blots. Treatment of the cells with the active 
DNAzyme led to increases in percentage of apoptotic cells and cytochrome c release 
from mitochondria, a hall marker of apoptosis. When combined with chemotherapeutics 
such as Taxol, the DNAzyme significantly sensitised a panel of cancer cells to apoptosis 
as measured by cell survival assay. In Taxol-resistant cells, down-regulation of bcl-xL 
expression by the DNAzyme reversed the chemo-resistant phenotype of the cancer 
cells. In a xenograft mouse model, the DNAzyme was delivered into the tumors via 
an ALZET osmotic pump and shown to chemosensitize PC3 tumor when treating with 
Taxol. The results from the present study demonstrate that bcl-xL DNAzyme treatment 
facilitates apoptosis in solid tumors and suggest the potential use of bcl-xL DNAzyme 
in combination with chemotherapeutics for cancer therapy.
INTRODUCTION
Apoptosis is a complex process resulting in the 
regulated destruction of a cell, which plays a major role 
in normal development, cellular response to injury and 
carcinogenesis [1]. It has been suggested that apoptosis 
is one of the major mechanisms of cell death in response 
to cancer therapy [2]. The Bcl‑2 family of proteins are 
among the most studied molecules in the apoptotic 
pathway. In this gene family, some are apoptosis inducers, 
including, bax, bak, bcl‑Xs, bad, bid, bik and hrk, and 
others, such as bcl‑2, bcl‑XL, bcl‑w, bfl‑1, brag‑1, Mcl‑1 
and A1 are apoptosis suppressors [3]. Bcl‑2 or bcl‑xL 
levels are elevated in a broad range of human cancers, 
indicating that these molecules may have a role in raising 
the apoptotic threshold in a broad spectrum of cancerous 
disorders. Expression of Bcl‑xL in the NCI 60 cell lines 
strongly correlated with resistance to most chemotherapy 
agents [4]. It has been suggested that a decrease in Bcl‑xL 
levels or the inhibition of Bcl‑xL activity might provoke 
apoptosis or at least sensitise cells to apoptotic death. In 
the absence of a clearly defined biochemical mechanism 
of action or activity for this family of cell‑death regulatory 
proteins (for which conventional inhibitors could therefore 
be developed), gene therapy and antisense approaches 
have become a reasonable alternative. For example, 
antisense oligonucleotides to bcl‑xL have been shown to 
be active in down‑regulation of the bcl‑xL expression, 
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leading to an increased chemosensitivity in a range of 
cancer cells [5]. 
An ideal oligonucleotide‑based gene inactivation 
agent targeting RNA would combine the self‑sufficient 
RNA digestion capability, such as “hammerhead” and 
“hairpin” ribozymes, with the relative biological resilience 
of the antisense oligodeoxynucleotides (ODN). Although 
DNA molecules with RNA cleavage activity have not 
been observed in nature, some have been derived as a 
result of an artificial evolutionary system known as in 
vitro selection [6‑9]. In an in vitro selection system, DNA 
liberated from its complementary strand is free to explore 
a full range of structural possibilities, some of which have 
been found to be capable of catalytic activity, including 
site specific RNA cleavage and ligation [10, 11]. The 10‑
23 DNA enzyme or DNAzyme was named from its origin 
as the 23rd clone characterised from the 10th cycle of in 
vitro selection [10]. This enzyme has a number of features, 
which endow it with tremendous potential for applications 
both in vitro and in vivo. These include its ability to cleave 
almost any RNA sequence with high specificity provided 
it contains a purine‑pyrimidine dinucleotide. This can be 
accomplished at very high kinetic efficiency with rates 
approaching and even exceeding those of other nucleic 
acid and protein endoribonucleases [10]. The ability of 
the 10‑23 DNAzyme to specifically cleave RNA with 
high efficiency under simulated physiological conditions 
has fuelled expectation that this agent may have useful 
biological application in a gene inactivation strategy 
[12‑16]. Recent studies showed promising clinical 
efficacy of the DNAzymes targeting c‑jun and EBV‑
encoded oncogene for treating various cancers [17, 18], 
which demonstrated the feasibility to use DNAzymes as 
therapeutics.
Here, we identified an active DNAzyme against the 
bcl‑xL gene by a multiplex selection. This DNAzyme was 
shown to effectively down‑regulate the Bcl‑xL expression 
in a range of cancer cells, thus overcome the anti‑apoptotic 
block and sensitized the cancer cells to chemotherapy in 
xenograft animal models. 
RESULTS
Identification of Cleavable sites in bcl‑xL mRNA.
DNAzymes were designed based on “10‑23” 
model (Fig 1A). A bcl‑xL cDNA clone (926 bp) was 
produced from the RNA sample of PC3 cells and used for 
screening the potential cleavable sites of DNAzymes. By 
bioinformatics analysis, 81 potential AU or GU sites were 
found and subjected to analyses on the thermodynamic 
stability of the enzyme‑substrate heteroduplex as predicted 
by the hybridisation free energy [19]. DNAzymes with 
Figure 1: Schematic description of “10‑23” DNAzyme. A, unmodified DNAzyme (PO‑DNAzyme); B, phosphorothioate‑modified 
DNAzyme (PS‑DNAzyme) as indicated by *. C, Multiplex In vitro selection of bcl‑xL DNAzymes. Bcl‑xl DNAzymes incubated with its 
RNA substrate for 60 minutes in the presence of 10 mM Mg2+ at 37oC. Primer extension was performed using the sequence‑specific primers 
along the bcl‑xl mRNA. The reactions were analysed alongside with DNA sequencing on a polyacrylamide gel. A representative gel is 
presented. V, molecular markers; C/A/T/G, sequencing ladders; 0/5/50/500 nM, a mixture of DNAzymes at the defined concentrations.
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the greatest heteroduplex stability indicated by a low 
free energy of hybridisation (calculated using the nearest 
neighbour method), was often found to have the greatest 
kinetic activity. As a result, 26 DNAzymes with ∆ G°<‑ 16 
kcal/mol were chosen for the further multiplex cleavage 
assay (sTable 1).
In order to select active DNAzymes, in vitro 
selection was performed using a multiplex method, 
which enables a pool of DNAzymes to be screened for 
their ability to access and cleave RNA substrate under 
simulated physiological conditions [20]. Based on the 
bioinformatics and physiochemical analyses as shown 
in sTable 1, twenty‑six DNAzymes (0nM, 5nM, 50nM 
and 500nM) and RNA substrate (400nM) were incubated 
for cleavage reaction and primer extension was then 
performed with Superscript II reverse transcriptase to 
define the cleavage sites within the bcl‑xL transcript. 
The sequencing ladders were used as a guide to attribute 
cleavage bands to specific DNAzymes. The relative 
cleavage strength of each DNAzyme was determined by 
intensity of the cleavage products. A representative gel 
was shown in Fig 1B. DNAzymes were ranked according 
to their cleavage ability at lowest concentration (5nM).The 
multiplex selection resulted in 10 active DNAzymes that 
could efficiently cleave the bcl‑xL mRNA (sTable 1).
Chemical modification of DNAzymes
To increase DNAzyme stability in cells, 1‑5 
phosphorothioate (PS) linkages were incorporated into 
each of the arms in DNAzyme (PS‑Dz, DT882). The 
DNAzymes’ stability in human serum was significantly 
improved with the increase of number of PS linkages (Fig 
2A). To examine if the modification had any impact on 
DNAzyme’s catalytic activity, we further performed a 
single turnover kinetic analysis of the modified DNAzyme. 
As shown in Fig 2B, the PS modification had decreased 
the cleavage efficiency (kobs) of the modified DNAzymes, 
compared with the unmodified one. To strike a balance 
between the stability and catalytic activity, we selected the 
3+3 PS modification scheme for the further cell and in 
vivo studies.
Effect of bcl‑xL DNAzymes on bcl‑xL expression
Using the modified version of 16 DNAzymes 
derived from the multiplex selection, we performed 
further testing for their ability to down regulate the 
bcl‑xL expression in cells. The assays were performed 
in PC3 cells (a prostate cancer cell line). After screening 
all 16 DNAzymes, three DNAzymes (DT 882, DT883, 
and DT884) exhibited a very strong inhibitory effect on 
bcl‑xL protein expression as shown in a representative gel 
(Figure 3A). An antisense control (ctggatccaaggctctaggt) 
and a negative control (scrambled arms of DT882, 
tggtgtgtgggctagctacaacgagttaataaa) were used in the 
screening. Based on the results of in vitro cell screening, 
we next selected one of the most active DNAzyme 
DT882 for further validation of its activity of down‑
regulation of bcl‑xL expression in a panel of cancer cell 
lines (PC3, prostate cancer; T24, bladder cancer; A549, 
lung carcinoma; CNE‑1, nasopharyngeal carcinoma; 
HCT116, colon cancer). Figures 3B showed that anti‑
bcl‑xL DNAzyme DT882 reduced the level of the bcl‑xL 
gene expression in the cell lines tested, which indicated 
that DT882 could be effectively transfected into the cells, 
found its target mRNA and inhibited bcl‑xL expression 
in cells.
Induction of apoptosis by Bcl‑xL specific 
DNAzyme
Having shown the DT882 inhibition of bcl‑xL 
expression in cancer cells, its effect on apoptosis of PC3 
cells was further examined. In the assay, same transfection 
procedure as in Western blotting assay was used, except 
those cells were subject to Annexin‑V staining after the 
overnight incubation with the DNAzyme. Fig 4A clearly 
Figure 2: Effect of phosphorothioate‑modification on 
DNAzyme stability in human serum and cleavage kinetics. 
A: the modified DNAzymes were incubated with the serum, 
extracted at the defined time points, and 32P‑labelled. Intact 
DNAzyme (%) was presented as a ratio of the band intensity 
at different time points to the band intensity at the 0 time point. 
B: the kinetic efficiency was measured under a single turnover 
condition and kobs was used as an indicator for cleavage activity.
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showed that there was a substantial increase in apoptosis 
population in the DNAzyme treated cells (23.17%), 
as compared with the control‑treated (an inactivated 
DNAzyme with scrambled arm sequences of DT882 ), 
indicating that the cells treated with the bcl‑xL DNAzyme 
was provoked to undergo apoptosis. To determine 
the effect of bcl‑xL DNAzyme on the early events of 
apoptosis caused by down‑regulation of bcl‑xL, the 
measurement of Cytochrome C release from the cells was 
performed. As shown in Figure 4B, DNAzyme‑mediated 
reduction of bcl‑xL in PC3 cells led to an increased release 
of Cytochrome C. This result not only confirmed the data 
from FACS analysis, but also validated the specificity of 
the DNAzyme in induction of apoptosis via mitochondria 
pathway in PC3 cells.
Chemosensitization of Cancer Cells with anti‑bcl‑
xL DNAzyme
The Bcl‑xL protein has been shown in a number 
of cell lines as a potent protector of cellular apoptosis 
induced by anti‑neoplastic agents. To examine if DT882 
could sensitise cancer cells to the effect of cytotoxic 
chemotherapy by down‑regulating bcl‑xL expression, 
cell survival was measured using MTS assays in a panel 
of cancer cells treated with either the DNAzyme alone 
or DNAzyme plus anti‑cancer agent Taxol. The results 
showed that the anti‑bcl‑xL DNAzyme DT882 sensitised 
all the cancer cells to Taxol treatment (Table 1). This 
sensitization led to about 150~260% increase of cell death 
in a range of cancer cell lines treated with DT882 plus 
Taxol, compared with that treated with Taxol alone. To 
examine if DT882 could reverse the Taxol‑resistance, 
a Taxol‑resistant cell line CNE2R (nasopharyngeal 
Figure 4: Induction of apoptosis by bcl‑xL DNAzyme. PC3 cells were transfected with DT882 and control. The cells were subjected 
to either Annexin‑V assay by FACS (A) or Western blot assay for cytochrome C (B). TMP, transfection reagent; Control, scrambled DT882 
control. C, a Taxol‑resistant cell line of nasopharyngeal carcinoma (CNE2R ) was used for MTS assays in the presence of a series of Taxol 
concentrations.
Figure 3: Inhibition of bcl‑xL protein expression by 
bcl‑xL DNAzymes. A. Screening of the selected DNAzymes 
(2 µM) using Western blotting was performed in PC3 cells 
and a representative blot was presented. Bcl‑xL antisense or 
a scrambled control were used as controls. B. Validation of 
inhibitory activity of Bcl‑xL DNAzyme (DT882) in different 
cancer cells was performed in PC3 (prostate cancer), T24 
(bladder cancer), A549 (lung cancer), CNE‑1 (nasopharyngeal 
carcinoma) and HCT116 (colon cancer) cells. TMP, transfection 
reagent; Control, scrambled DT882.
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carcinoma) were assayed for possible drug resistance 
reversal. As shown in Figure 4C, while the Taxol treatment 
in a range of concentrations did not cause cell death of the 
resistant cells or the control‑treated resistant cells, DT882 
treated resistant cells showed a significant reduction in cell 
survival, indicating that down‑regulation of the bcl‑xL in 
the Taxol‑resistant cells could restore the cellular response 
to the chemotherapeutics.
Chemosensitization in human tumour xenograft 
model by anti‑bcl‑xL DNAzyme DT882.
In order to demonstrate if DNAzyme‑mediated 
down‑regulation of the bcl‑xL expression resulted in 
chemosensitization of tumour cells to anticancer drugs 
in vivo, a murine model with human PC3 prostate cancer 
Figure 5: Chemosensitization of PC3 human xenograph prostate cancer by anti‑bcl‑xL DNAzyme. A: Nude mice bearing 
established, subcutaneously growing PC3 tumour xenograft either remained untreated (saline) or were treated with DT882, antisense 
control, Taxol or DNAzyme + Taxol and AS+ Taxol. DNAzyme DT882 or AS was delivered using an osmotic pump and Taxol was 
administrated via i.p. route weekly. Tumour size was measured at the time points indicated. AS, antisense control (25). B: DNAzyme 
(DT882) was extracted from tumor tissues, plasma and the remaining solution of the pumps, labelled and assayed on PAGE.
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xenograft was used to determine the sensitivity to the 
chemotherapeutic. In the experiments, seven groups of 
mice (8 mice per group) (Saline, DNAzyme, AS, Control, 
Taxol, Taxol + DNAzyme, and Taxol + AS ) were 
employed. When tumours reached an average volume of 
100‑200 mm3, an Alzet osmotic pump, which was used 
as a delivery vehicle for DNAzyme oligonucleotide in 
tumour bearing mice, was surgically implanted in the 
peritoneum of the mouse via the abdominal route. As 
shown in Fig 5A, the combinational use of DT882 and 
Taxol markedly inhibited PC3 tumour growth compared 
with the groups of DNAzyme alone, Taxol alone or control 
plus Taxol. 
To examine the in vivo stability of the DNAzyme 
and the pump delivery efficiency, the DNAzyme 
oligonucleotide was extracted from the tumor tissues, 
plasma and the remaining solution of the pumps in the 
mice treated with DT882 plus Taxol (day 14), and labelled 
with γ‑‑32P‑ATP. Analysis showed that the DNAzyme was 
stable over the treatment period and the Alzet osmotic 
pump provided a consistent delivery of the DNAzyme in 
vivo (Fig 5B).
DISCUSSION
DNAzymes have been shown to effectively suppress 
gene expression both in vitro and in vivo [21]. Limited 
therapeutic efficacy has been demonstrated in patients in 
studies targeting c‑jun and EBV‑LMP1 [17, 18]. In the 
present report, we present a comprehensive study in which 
an active DNAzyme targeting bcl‑xL gene was identified 
and validated through in vitro selection to in vivo testing, 
showing clear experimental evidence that the Bcl‑xL 
DNAzyme could be an effective chemo‑adjuvant agent 
for potential clinical applications in cancer chemotherapy. 
Targeting a DNAzyme to a particular mRNA is 
generally a multi‑step process. In our previous study, a 
multiplex selection approach was devised to facilitate the 
selection of the accessible sites for DNAzymes within the 
target mRNA [20], but only at the in vitro level. Here, we 
successfully applied this methodology and further proved 
that there was a consistency between the in vitro cleavage 
activity and in vivo efficacy of the DNAzymes. Thus, our 
study provided a streamline approach to therapeutic uses 
of DNAzymes. 
Despite the range of anti‑cancer studies using 
nucleic acid‑based agents, one common factor necessary 
for the success of therapeutic uses of those agents is the 
ability to delivery of the agents in a precise and dependable 
manner. The antitumor effects of the therapeutic agents are 
influenced by schedule of drug administration. In majority 
of the studies testing anti‑cancer oligonucleotides, intra‑
tumoral injection has been the method of the choice to 
deliver oligonucleotides [22], which was somewhat 
invasive and less efficient. In this study, we surgically 
implanted the ALZET osmotic pump adjacent to the 
tumor, permitting continuous, controlled dosing, thus 
enabling us to achieve steady state conditions and accurate 
delivery of the DNAzyme over prolonged periods of time 
and to show a significant effect of chemosensitization by 
the DNAzyme to Taxol treatment. 
To date, there have been substantial amount of 
preclinical and clinical studies in search for the inhibitors 
of Bcl‑2 family, among which one Bcl‑2 antisense and 
three small molecule inhibitors are being tested in clinical 
trials [23, 24]. However, it has been well recognized that 
the agents with high specificity tend to induce cancer 
drug resistance, while broader acting agents could cause 
unwanted toxicity. Considering that the anti‑apoptotic Bcl‑
2 family is a large and redundant family of proteins, some 
of which have been shown to contribute to drug resistance 
in cancer cells [25, 26], inhibition of multiple Bcl‑2 family 
members would be necessary in order to optimize the 
therapeutic effect. Importantly, previous studies showed 
that paclitaxel (Taxol) causes phosphorylation and 
inactivation of Bcl‑2 [31‑34]. Phosphorylation of Bcl‑2 
takes place only during mitotic arrest and the duration of 
the arrest is important for cell killing by paclitaxel/Taxol 
[35, 36]. However, Bcl‑2 can be substituted by Bcl‑xL 
[37], which underscores the importance to decrease Bcl‑
xL levels in Taxol‑treated cells. This decrease actually 
increases sensitivity to Taxol as now shown by current 
work. Thus, our strategy further confirm that one anti‑
apoptotic protein can be substituted by the other, providing 
evidence that the Taxol resistance can be overcome by 
targeting Bcl‑xL.
In conclusion, we present a novel agent that 
catalytically cleave the Bcl‑xL mRNA, one of the 
important members of Bcl‑2 family, thus add another 
candidate of inhibitors of anti‑apoptotic Bcl‑2 family with 




PC3 (prostate adenocarcinoma), T24 (bladder 
carcinoma), MDA‑MB‑231 (Breast cancer), A549 (lung 
carcinoma), B9‑58 (lymphoma) and HCT116 (colon 
carcinoma) human cancer cell lines were obtained 
from the American Type Culture Collection. CNE1 
(nasopharyngeal carcinoma) is the EB virus negative 
low differentiated nasopharyngeal squamous carcinoma 




All the oligonucleotides were made by TriLink 
BioTechnologies (San Diego, CA) and purified by gel 
electrophoresis for in vitro studies and by HPLC for cell‑
based assays and in vivo studies.
Design and thermodynamic analysis of DNAzymes
DNAzyme sequences for each target are assembled 
using the 10‑23 catalytic motif [ggctagctacaacga] and 
hybridising arms specific for each site along the target 
RNA transcript (Fig. 1A). The length of each arm is 
usually fixed at 9 bases; however, these can be shortened 
or lengthened depending on their individual predicted 
hybridisation free energy. Each DNAzyme oligonucleotide 
is designed to target purine‑uracil (RU). In most cases 
we ignore purine‑cytosine sites as in our experience 
they are less reactive than RU sites, particularly AC 
junctions [28]. The potential DNAzymes were subjected 
to thermodynamic analyses (hybridization free energy and 
Tm) [19]. 
Multiplex selection of active DNAzymes in vitro
DNAzyme target site selection was described 
previously [20]. Briefly, linear template DNA 
for the production of the bcl‑xL transcript was 
prepared by PCR in a mixture containing 10 pM 
cDNA, 1 µM of the forward T7 phage promoter 
primer [TAATACGACTCACTATAGGGAGA‑
AAGATTCTGAAGGGAGAG] and 1 µM of the reverse 
primer [CGGGTTTCTCCTGGTGGCAATG]. The 
reaction was carried out over 25 temperature cycles 
at 95oC for 30 s, 60oC for 90 s, and 72oC for 60 s in a 
solution containing 16.6 mM (NH4)2SO4, 67 mM Tris‑
HCl (pH 8.8), 6.7 mM MgCl2, 0.87 units of AmpliTaq 
DNA polymerase (Perkin Elmer) and 300 µM each 
of dGTP, dATP, dTTP, dCTP. PCR products were 
electrophoresed in a 1% agarose gel alongside appropriate 
size/ mass standards and visualised by ethidium 
fluorescence. The illuminated amplicon bands were then 
excised from the agarose slab and extracted using Gene 
Clean (Bio 101). Template DNA was then redissolved in 
diethyl pyrocarbonate (DEPC) treated RNase free water 
and the concentration adjusted to approximately 100ng.
µl‑1.
For RNA transcription, reaction was performed with 
100 ng of purified template DNA and T7 RNA polymerase 
at 37oC for 3 h using an RNA transcription kit (Epicentre). 
After the 3 hour incubation the DNA template was 
degraded by the addition of 1 MBU of RNase‑free DNase 
I and further 15 min incubation at 37oC. This reaction was 
then terminated by adding an equal volume of phenol/ 
chloroform/ isoamyl alcohol. The RNA contained in the 
aqueous phase could be used directly in the multiplex 
cleavage reaction or precipitated in 0.3M sodium acetate 
and two volumes of absolute ethanol. 
Multiple DNAzyme oligonucleotides (0.5 nM‑
0.5 µM) and synthetic RNA substrate (0.2 µM) were 
pre‑equilibrated separately for 10 min at 37oC in equal 
volumes of 50 mM Tris‑HCl, pH 7.5, 10 mM MgCl2, 
150 mM NaCl and 0.01 % SDS. The reaction was then 
initiated by mixing the DNAzymes and substrate together. 
After an hour the reactions were stopped by emersion in 
ice and precipitation in 0.3 M sodium acetate and two 
volumes of ethanol. 
Primer extension analysis was then performed on 
DNAzyme cleaved RNA using SuperScriptII reverse 
transcriptase (Life Technologies). Two primers were 
designed for the extension reactions along the bcl‑
xL RNA [PE1: GTTTCTCCTGGTGGCAATG; PE2: 
CCATCCCGGAAGAGTTCA]. In each reaction 2 pmol 
of 32P‑labelled primer was combined with 400 nM of 
RNA and denatured at 90oC for 5 min. For extension with 
Superscript reverse transcriptase, the primer was allowed 
to anneal slowly between 65oC and 45oC before adding 
the 1st strand buffer, dithiothreitol, deoxyribonucleotides 
and enzyme (according to the manufacturer’s instructions). 
This mixture (final volume 20 µl) was then incubated for 
1h at 45oC before being transferred to ice. 
Sequencing fragments corresponding to each 
segment of the target were also generated by primer 
extension on the double stranded DNA template in 
the presence of chain terminating dideoxynucleotides 
(ddNTP). In these four reactions the dNTP concentration 
was reduced to 2.5 µM while being supplemented by 
either 10 µM ddGTP or 100 µM ddATP or 200 µM ddTTP 
or 100 µM ddCTP in 16.6 mM(NH4)2SO4, 67 mM Tris‑
HCl (pH 8.8), 6.7 mM MgCl2, 0.87 units of Taq DNA 
polymerase and 1.0 pmol of the 32P‑labelled primer. This 
reaction was performed as a linear amplification over 25 
temperature cycles at 95o C for 30 s, 60° C for 90 s, and 
72° C for 60 s.
After primer extension, samples were combined 
with an equal volume of stop buffer (formamide/EDTA/
loading dye) before electrophoresis on a 6% denaturing 
polyacrylamide gel. The corresponding image could then 
be revealed and the band intensity quantified at each 
position with Phosphorimager and ImageQuant software 
(Molecular Dynamics). 
DNAzyme stability assay and kinetic analysis.
The DNAzyme (DT882) was modified with 1, 
3 or 5 phosphorothioate (PS) linkages respectively.
Unmodified and PS‑modified DNAzymes were incubated 
at a final concentration of 10 µM in 100% human AB 
serum (Sigma, St. Louis, MO) at 37°C. Aliquots (10 
µl) of the incubation mixture were removed at 0, 2, 8, 
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24 and 48 hours and diluted in 290 µl of 10 mM Tris/1 
mM EDTA, pH 8.0, buffer (TE buffer). The diluted 
DNAzyme was extracted by sequentially adding 150 µl 
phenol and 150 µl chloroform with vortexing. Samples 
were centrifuged at 11,300g for 10 minutes, and 100 
µl supernatant was collected. Aliquots of the aqueous 
supernatant were labeled with 32P and electrophoresed 
on a 16% polyacrylamide gel. Labeled DNAzyme bands 
were quantified using Molecular Dynamics ImageQuant 
software (Sunnyvale, CA), and the recovered DNAzyme 
was expressed as a percentage of the DNAzyme diluted 
directly into TE buffer.
The in vitro activity of DNAzymes was determined 
by measuring the rate of RNA cleavage under single 
turnover condition. The 32P‑labelled RNA transcripts to 
be used in the cleavage reaction were produced utilising 
the RNA transcription kit (Epicentre). The transcripts were 
electrophoresed on a 16% denaturing PAGE and bands 
were excised and gel purified. The observed constant (kobs) 
is the rate of cleavage and it was calculated by regression 
analysis of the progress curve using the following 
equation:
[P] = [P]∞(1 ‑ e‑1kobst)
where [P] is the cleavage yield, [P∞] is the final 
cleavage yield, and t is the reaction time [29]. Cleavage 
reactions were performed over multiple time points. 
DNAzyme transfections 
To facilitate delivery of DNAzyme 
oligonucleotides into cells, a cationic porphyrin, tetra 
meso (4‑methylpyridyl) porphyrin (TMP), was used as a 
transfection reagent for intracellular delivery [30]. Briefly, 
0.8 x 105 cells were seeded in a 60‑mm culture dish and 
incubated at 37oC, 5% CO2 overnight. DNAzyme and 
control molecules were transfected into cells with TMP at 
a charge ratio of 3. The final concentration of DNAzyme in 
the transfection mix was 2 µM in 2 ml of medium without 
serum. After 4 hours, the cells were replaced with fresh 
culture medium. Twenty‑four hours after transfection, 
the cells were harvested for Western blot and cell biology 
analyses.
Western analysis 
Protein was extracted from the transfected cells in 
RIPA buffer (50 mM Tris‑HCl, pH 8, 150 mM NaCl, 0.1% 
SDS, 1% NP‑40, 0.5% sodium deoxycholate, 0.57 mM 
PMSF and 1 µg/ml aprotinin). Protein samples (40 µg) 
were run on 12% SDS‑PAGE gels (BioRad), transferred to 
nylon membranes and immunoblotted with the following 
antibodies: anti Bcl‑xL mouse monoclonal antibody (H‑
5, Santa Cruz), anti‑Cytochrome C rabbit polyclonal 
antibody (H‑104, Santa Cruz) and anti‑β‑actin monoclonal 
antibody (AC‑74, Sigma). Binding of primary antibodies 
was detected with goat anti‑rabbit or anti‑mouse horse 
radish peroxidase conjugated secondary antibodies 
(Santa Cruz). This binding was visualized with the ECL 
western blotting detection reagents (Amersham Pharmacia 
Biotech, England) on exposure to chemiluminescent film.
Apoptosis and cell survival assays
To determine apoptosis induced by DNAzymes, 
Annexin‑V‑FUOS Kit was used to detect apoptotic cells 
by FACS, according to the manufacturer’s instruction 
(Roche). Apoptotic cells were quantified using a FACScan 
flow cytometer (Becton–Dickinson). 
Chemosensitization effect of DNAzymes on cancer 
cells was examined using MTS assay. Cancer cells were 
treated with DNAzyme/TMP complex for 4 hours. The 
medium was then replaced with fresh DMEM containing 
10% FBS and 100 nM Taxol, and further incubated for 72 
hours. MTS assays were performed for cell viability of all 
the samples. 
Detection of cytosolic Cytochrome C expression 
in PC3 cells
Transfected cells were harvested by centrifugation at 
200 g for 5 minutes at 4° C. The cell pellets were washed 
once with ice‑cold phosphate‑buffered saline (PBS) and 
resuspended with 5 volume of buffer containing 20 mM 
HEPES‑KOH, pH 7.5; 10 mM KCl; 1.5 mM MgCl2; 1 
mM sodium EDTA; 0.1% SDS; 1 mM dithiothreitol; and 
0.1 mM phenylmethyl sulfonyl fluoride containing 250 
mM sucrose. The cells were homogenized with a 22‑gauge 
needle, and the homogenates were centrifuged at 1000g 
for 10 minutes at 4°C to remove nuclei, unbroken cells, 
and large membrane fragments. The supernatant was 
centrifuged once more at 10,000g at 4 °C for 30 min. The 
supernatant cytosolic fraction was collected, quantitated 
and used in Western analysis.
In vivo mouse model and DNAzyme treatment
Four‑week‑old female Balb/C nude mice were 
obtained from the Animal Resources Center (Perth, 
Australia) and were housed and maintained in compliance 
with the National Health and Medical Research 
Council Statement on Animal Experimentation and the 
requirements of the New South Wales State legislation. 
Four groups of mice (8 mice per group) (Saline, 
DNAzyme, Taxol, Taxol + DNAzyme) were employed. 
At day 1: acclimatised nude male Balb/C athymic mice 
were injected with 1x 106 PC3 cells suspended in 0.1 
ml Matrigel in the right hind leg under methoxyfluorane 
anesthesia. Tumour growth was measured twice weekly 
using digital callipers and tumour volume is calculated 
Oncotarget9047www.impactjournals.com/oncotarget
using the (l * w * h* π/6) formula. When tumours reached 
an average volume of 100‑200 mm3, an Alzet osmotic 
pump (BioScientific), which was used as a delivery vehicle 
for DNAzyme oligonucleotide in tumour bearing mice, 
was surgically implanted in the peritoneum of the mouse 
via the abdominal route. The Alzet model1002 pump is 
a capsule shaped pump (1.5 x 0.6 cm) and delivered a 
total volume of 0.5 ml at a rate of 0.25 µl/hr over a period 
of 14 days. The pump was filled with a saline solution 
containing DNAzyme oligonucleotide, which resulted 
in a dose rate of 12.5 mg/kg/d. Some mice received 
sub‑optimal doses of 25 mg/kg Taxol by intraperitoneal 
route in a 200µl injection once weekly post‑surgery for 
the duration of the study. At the end of 14d, mice were 
euthanized by cervical dislocation and tumours harvested. 
Tumours were weighed, snap‑frozen and stored at 
–80oC till analysis. To analyse the concentration of the 
DNAzyme, the DNAzyme oligonucleotide was extracted 
from tumor tissue, plasma and remaining solution in the 
pumps with phenol/chloroform and precipitated with 
ethanol. The extracted DNAzyme was labelled with γ‑32P‑
ATP by T4 polynucleotide kinase and assayed on PAGE.
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